Teva CEO: Emalex Acquisition to be Accretive Very Fast

TEVA teva pharm CEO francis to Reuters: we expect emalex acquisition to be accretive "very fast" but unlikely in 2027 Teva pharm CEO francis: biosimilar launches in coming years to be main growth driver of teva's generics drugs business - Trying to understand what Trump administration is seeking to do on drug tariffs but "we have a good seat at the table" as a "major player in the U.S.

Healthcare ecosystem" - In talks with U.S. government on most favoured nation issue and how that could impact teva; "right now we are in a good position"